IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12103917 B1

PDFFull Text
Date of Patent:
Oct. 01, 2024

Filed:

Jun. 08, 2021

Modulators of myocyte lipid accumulation and insulin resistance and methods of use thereof

Applicant:

The Trustees of the University of Pennsylvania, Philadelphia, PA (US);

Inventors:

Daniel Kelly, Philadelphia, PA (US);

Richard Vega, Orlando, FL (US);

Hampton Sessions, Orlando, FL (US);

Teresa Leone, Philadelphia, PA (US);

Byungyong Ahn, Wallingford, PA (US);

Satyamaheshwar Peddibhotla, Orlando, FL (US);

Assignee:

THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, Philadelphia, PA (US);

Attorneys:

Howson & Howson, LLP

Kathleen D. Rigaut

Primary Examiner:

Kristin A Vajda

Int. Cl.
CPC ...
C07D 277/46 (2006.01); A61K 31/426 (2006.01); A61K 31/428 (2006.01); A61K 31/4439 (2006.01); A61K 31/454 (2006.01); A61K 31/496 (2006.01); A61K 31/5375 (2006.01); A61K 31/5377 (2006.01); A61K 31/541 (2006.01); A61K 45/06 (2006.01); A61P 3/04 (2006.01); A61P 3/10 (2006.01); C07D 277/82 (2006.01); C07D 295/185 (2006.01); C07D 417/04 (2006.01); C07D 417/12 (2006.01);
U.S. Cl.
CPC ...
C07D 277/46 (2013.01); A61K 31/426 (2013.01); A61K 31/428 (2013.01); A61K 31/4439 (2013.01); A61K 31/454 (2013.01); A61K 31/496 (2013.01); A61K 31/5375 (2013.01); A61K 31/5377 (2013.01); A61K 31/541 (2013.01); A61K 45/06 (2013.01); A61P 3/04 (2018.01); A61P 3/10 (2018.01); C07D 277/82 (2013.01); C07D 295/185 (2013.01); C07D 417/04 (2013.01); C07D 417/12 (2013.01);
Abstract

Formulations and methods for reducing blood glucose and/or increasing insulin signaling in a subject have been developed. The formulations include SBI-477 and compounds based on SBI-477 i.e., SBI-477 analogs (collectively, SBI-477 compounds) and/or Mondo family inhibitors, in an effective amount to inhibit intracellular lipid accumulation and/or increase cellular glucose uptake when compared to levels in a control subject not administered the composition. Also disclosed are methods of reducing intracellular lipid accumulation and/or increase glucose uptake in a subject in need thereof. The method includes administering to the subject an effective amount of SBI-477 compounds and/or Mondo family inhibitor to reducing intracellular lipid accumulation and/or increase glucose uptake in the subject. Also disclosed are method for treating one or more Myc-driven cancers, including neuroblastoma, lung squamous cell carcinoma/lung adenocarcinoma, liver hepatocellular carcinoma, colon adenocarcinoma, acute myeloid leukemia, and breast invasive carcinoma.

Find Patent Forward Citations

Loading…